Skip to content

Parcel Biosciences

2 viewers · 30d

Total raised

$13.2M

+$13.2M this year

1 filing since 2026 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $13.2M
ROUNDS
1
INVESTORS
52
FOUNDED
2024
HQ
San Francisco, CA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
2

AI overview

Updated

Parcel Biosciences is a seed-stage biotechnology startup founded in 2023, focused on developing next-generation RNA therapeutics. The company is creating a nanoparticle-free delivery system for mRNA medicines, aiming to overcome the technical limitations of current lipid nanoparticle technologies. This innovative approach is designed to enable targeted delivery of therapeutics to specific cell types, expanding the potential applications of mRNA beyond vaccines.

What sets it apart

The company's core innovation is its STAmP™ platform, a delivery system that protects mRNA from degradation without using nanoparticles. This method allows for precise, cell-specific targeting and is designed to be safer for systemic applications and higher doses compared to traditional delivery technologies.

Funding history

1 round
EquityFeb 6, 2026
Form D
+$13.2M$13.2M total

Latest SEC filings

via EDGAR · CIK 0002113766
Form D · Feb 6, 2026View on EDGAR

Products

1 tracked

STAmP™ (Stabilization and Targeting by Annealing mRNA to ParcelOligos) Platform

mRNA Delivery Platform

The STAmP™ platform is a non-viral, nanoparticle-free delivery system for mRNA. It utilizes chemically modified oligonucleotides, called ParcelOligos, which anneal directly to the mRNA payload. This process stabilizes the mRNA and allows for the attachment of targeting ligands (such as GalNAc or C16) to guide the therapeutic to specific cells and tissues.

  • Provides mRNA stability without encapsulation in lipid nanoparticles
  • Enables precise, cell-specific targeting via customizable ligands
  • Designed to support higher therapeutic doses and systemic applications
  • Aims to reduce potential side effects associated with LNP delivery systems

Links

LinkedInSEC EDGAR filings